I-MAB(IMAB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMAB I-MAB

Market Closed 11-22 16:00:00 EST

0.9397

-0.0193

-2.01%

盘后0.9397

+0.00000.00%

19:54 EST

High0.9795	Low0.9100	Vol276.93K
Open0.9249	D1 Closing0.9590	Amplitude7.25%
Mkt Cap76.52M	Tradable Cap45.11M	Total Shares81.43M
T/O258.93K	T/O Rate0.58%	Tradable Shares48.01M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"IMAB","market":"US","secType":"STK","nameCN":"I-MAB","latestPrice":0.9397,"timestamp":1732309200000,"preClose":0.959,"halted":0,"volume":276932,"hourTrading":{"tag":"盘后","latestPrice":0.9397,"preClose":0.9397,"latestTime":"19:54 EST","volume":38,"amount":35.9632,"timestamp":1732323253759},"delay":0,"floatShares":48007714,"shares":81434680,"eps":-1.007785,"marketStatus":"Market Closed","change":-0.0193,"latestTime":"11-22 16:00:00 EST","open":0.9249,"high":0.9795,"low":0.91,"amount":258928.1245092,"amplitude":0.072471,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.007785,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732525200000},"marketStatusCode":7,"adr":0,"adrRate":2.3,"listingDate":1579237200000,"exchange":"NASDAQ","adjPreClose":0.959,"preHourTrading":{"tag":"盘前","latestPrice":0.9599,"preClose":0.959,"latestTime":"08:16 EST","volume":130,"amount":123.9400032,"timestamp":1732281403564},"postHourTrading":{"tag":"盘后","latestPrice":0.9397,"preClose":0.9397,"latestTime":"19:54 EST","volume":38,"amount":35.9632,"timestamp":1732323253759},"volumeRatio":0.9318693446129276,"impliedVol":1.0592,"impliedVolPercentile":0.4246},"requestUrl":"/m/hq/s/IMAB","defaultTab":"news","newsList":[{"id":"2485498432","title":"I-Mab to Participate at the Piper Sandler Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2485498432","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485498432?lang=en_us&edition=fundamental","pubTime":"2024-11-21 20:00","pubTimestamp":1732190400,"startTime":"0","endTime":"0","summary":"The 36th Annual Healthcare Conference will be held in New York, December 3-5, 2024. ROCKVILLE, Md., Nov. 21, 2024 /PRNewswire/ -- I-Mab , a U.S.-based global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024.Piper Sandler 36th Annual Healthcare Conference Presentation Details. Sean Fu, PhD, MBA, Chief Executive Officer  Phillip Dennis, MD, PhD, Chief Medical Officer. For more information, please contact your Piper Sandler representative.I-Mab  is a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YY4cMKzXvpZlyMc6OlKWdw--~B/aD0xNjA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/eb81d0c969528762bc858c941b7a51e6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YY4cMKzXvpZlyMc6OlKWdw--~B/aD0xNjA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/eb81d0c969528762bc858c941b7a51e6"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/mab-participate-piper-sandler-healthcare-120000465.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mab-participate-piper-sandler-healthcare-120000465.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4137","BK4505","BK4526","IMAB","BK4535","BK4139","HCSG"],"gpt_icon":1},{"id":"2484336256","title":"I-Mab Third Quarter 2024 Earnings: US$0.25 loss per share (vs US$0.57 loss in 3Q 2023)","url":"https://stock-news.laohu8.com/highlight/detail?id=2484336256","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484336256?lang=en_us&edition=fundamental","pubTime":"2024-11-17 21:21","pubTimestamp":1731849665,"startTime":"0","endTime":"0","summary":"NasdaqGM:IMAB Earnings and Revenue History November 17th 2024. All figures shown in the chart above are for the trailing 12 month  period. Looking ahead, revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.The company's shares are down 5.5% from a week ago.Before we wrap up, we've discovered 4 warning signs for I-Mab that you should be aware of.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mab-third-quarter-2024-earnings-132105479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IMAB"],"gpt_icon":0},{"id":"2483511321","title":"I-Mab Price Target Maintained With a $8.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483511321","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483511321?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:39","pubTimestamp":1731670740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMAB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 15, 2024 06:39 ET (11:39 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMAB"],"gpt_icon":0},{"id":"2483872570","title":"IMAB Q3 GAAP EPS Of $(0.11) Vs. $(0.04) YoY, Cash And Cash Equivalents, And Short-term Investments Of $184.4M Expected To Be Sufficient To Fund Its Current Operating Plan Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2483872570","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483872570?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:51","pubTimestamp":1731588695,"startTime":"0","endTime":"0","summary":"IMAB Q3 GAAP EPS Of $(0.11) Vs. $(0.04) YoY, Cash And Cash Equivalents, And Short-term Investments Of $184.4M Expected To Be Sufficient To Fund Its Current Operating Plan Into 2027","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/24/11/41969700/imab-q3-gaap-eps-of-0-11-vs-0-04-yoy-cash-and-cash-equivalents-and-short-term-investments-of-184-","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"IMAB Q3 GAAP EPS Of $(0.11) Vs. $(0.04) YoY, Cash And Cash Equivalents, And Short-term Investments Of $184.4M Expected To Be Sufficient To Fund Its Current Operating Plan Into 2027","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMAB"],"gpt_icon":0},{"id":"2483887932","title":"I-Mab: Estimated Cash Runway Into 2027, Based on $184.4 Mln in Cash & Cash Equivalents, & Short-Term Investments as of Sept30, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483887932","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483887932?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:00","pubTimestamp":1731585617,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUA6ZYJSH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMAB","BK4526","BK4505","BK4535"],"gpt_icon":0},{"id":"2483876746","title":"Press Release: I-Mab Reports Third Quarter 2024 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483876746","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483876746?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:00","pubTimestamp":1731585600,"startTime":"0","endTime":"0","summary":"-- Givastomig data presented at ESMO 2024 and SITC 2024 highlights. -- On track to dose first patient in randomized Phase 2 study of uliledlimab. equivalents, and short-term investments as of September 30, 2024. \"I-Mab is making excellent progress in advancing the development of our pipeline projects, supported by our strong cash balance, streamlined operating model, and a focused in-licensing strategy,\" said Dr. Sean Fu, CEO and Board Member of I-Mab. \"In addition, Phase 1 data presented this year for uliledlimab, givastomig, and ragistomig at four international medical conferences highlight the strength of our early data sets for each program. These results have provided us with a strong foundation for advancing each molecule into expanded clinical trials, including Phase 2 studies, in the next year.\". Uliledlimab : Initiating a randomized Phase 2 combination study in first-line metastatic non-small cell lung cancer . Uliledlimab  is an antibody designed to target CD73, the rate-limi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","BK4505","BK4535","IMAB","BK4139"],"gpt_icon":1},{"id":"2483709820","title":"I-Mab: Qtrly Net Loss per Ads $0.25","url":"https://stock-news.laohu8.com/highlight/detail?id=2483709820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483709820?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:18","pubTimestamp":1731583122,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML0GM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","BK4526","BK4535","IMAB"],"gpt_icon":0},{"id":"2482088428","title":"I-Mab    expected to post a loss of 22 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482088428","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482088428?lang=en_us&edition=fundamental","pubTime":"2024-11-12 22:20","pubTimestamp":1731421205,"startTime":"0","endTime":"0","summary":"* I-Mab     is expected to report resultson November 14 for the period ending March 31 2024   *    * LSEG's mean analyst estimate for I-Mab is for a loss of 22 cents per share.    * The current averag","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"I-Mab    expected to post a loss of 22 cents a share - Earnings Preview","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMAB"],"gpt_icon":0},{"id":"2481493408","title":"I-Mab Makes Interim CEO Sean Fu Permanent","url":"https://stock-news.laohu8.com/highlight/detail?id=2481493408","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481493408?lang=en_us&edition=fundamental","pubTime":"2024-11-06 21:56","pubTimestamp":1730901409,"startTime":"0","endTime":"0","summary":"I-Mab (IMAB) said Wednesday that Sean Fu permanently took over the chief executive position after serving interim since July.The appointment was effective Friday last week, I-Mab said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["5G4.SI","IMAB","BK4139","BK4526","BK4505","BK4535"],"gpt_icon":0},{"id":"2481605869","title":"I-Mab Appoints New CEO to Drive Cancer Therapy Goals","url":"https://stock-news.laohu8.com/highlight/detail?id=2481605869","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481605869?lang=en_us&edition=fundamental","pubTime":"2024-11-06 20:35","pubTimestamp":1730896513,"startTime":"0","endTime":"0","summary":"I-MAB (IMAB) has released an update. I-Mab, a global biotech firm focused on cancer immunotherapies, has appointed Sean Fu as its permanent CEO. Wi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/i-mab-appoints-new-ceo-to-drive-cancer-therapy-goals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/i-mab-appoints-new-ceo-to-drive-cancer-therapy-goals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IMAB","BK4526","BK4505","BK4535"],"gpt_icon":0},{"id":"2481677786","title":"I-Mab Appoints Sean Fu, Phd, MBA, as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2481677786","media":"THOMSON REUTERS","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481677786?lang=en_us&edition=fundamental","pubTime":"2024-11-06 20:00","pubTimestamp":1730894407,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nTUA8KSLMP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4526","IMAB","BK4535","BK4505","BK4139"],"gpt_icon":0},{"id":"2481670228","title":"I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2481670228","media":"PR Newswire","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481670228?lang=en_us&edition=fundamental","pubTime":"2024-11-06 20:00","pubTimestamp":1730894400,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md., Nov. 6, 2024 /PRNewswire/ --I-Mab  , a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that Sean  Fu, PhD, MBA has been appointed as the Company's permanent Chief Executive Officer  effective November 1, 2024. Dr. Fu has served as Interim CEO since July 15, 2024. Dr. Fu will continue to serve as a member of the Board of Directors of I-Mab.\"Sean's appointment serves as a significant step towards further realizing I-Mab's mission of delivering transformative therapies to patients worldwide. He has embraced his role as Interim CEO and quickly proven to be a strategic and effective leader\", said Mr. Wei Fu, Chairman of the Board of Directors of I-Mab. \"Sean's broad experience across all aspects of biopharmaceutical product development, partnering transactions, organizational leadership, and his track record as an innovative entrepreneur make him the right choice t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YY4cMKzXvpZlyMc6OlKWdw--~B/aD0xNjA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/eb81d0c969528762bc858c941b7a51e6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YY4cMKzXvpZlyMc6OlKWdw--~B/aD0xNjA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/eb81d0c969528762bc858c941b7a51e6"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/mab-appoints-sean-fu-phd-120000750.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mab-appoints-sean-fu-phd-120000750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4526","IMAB","BK4535","BK4505"],"gpt_icon":1},{"id":"2481656368","title":"I-Mab -  on Nov 1 Federal Jury Found in Favor of Defendants in Bifurcated Trial Relating to Some of Co's Trade Secret Information","url":"https://stock-news.laohu8.com/highlight/detail?id=2481656368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481656368?lang=en_us&edition=fundamental","pubTime":"2024-11-06 05:02","pubTimestamp":1730840563,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nFWN3MC0ZI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4526","BK4505","BK4535","IMAB","BK4139"],"gpt_icon":0},{"id":"2479796701","title":"I-Mab to Release Q3 2024 Financial Results on November 14, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2479796701","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479796701?lang=en_us&edition=fundamental","pubTime":"2024-10-31 19:00","pubTimestamp":1730372400,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab  , a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time.The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year financial results to discuss its clinical pipeline, corporate strategy, and objectives. Information about financial results, conference calls, webcasts, and other information is posted on the Company's website.I-Mab Investor & Media ContactsTyler EhlerSenior Director, Investor RelationsIR@imabbio.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YY4cMKzXvpZlyMc6OlKWdw--~B/aD0xNjA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/eb81d0c969528762bc858c941b7a51e6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YY4cMKzXvpZlyMc6OlKWdw--~B/aD0xNjA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/eb81d0c969528762bc858c941b7a51e6"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/mab-release-q3-2024-financial-110000518.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mab-release-q3-2024-financial-110000518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SQQQ","MNQmain","PSQ","QLD",".IXIC","IMAB","NQmain","BK4139","TQQQ","BK4526","QID","BK4505","BK4535"],"gpt_icon":1},{"id":"2479309203","title":"I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2479309203","media":"PR Newswire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479309203?lang=en_us&edition=fundamental","pubTime":"2024-10-30 19:00","pubTimestamp":1730286000,"startTime":"0","endTime":"0","summary":"- Poster to be presented in alate-breaking abstract session at the Society for Immunotherapy of Cancer  on Saturday, November 9, 2024. ROCKVILLE, Md., Oct. 30, 2024 /PRNewswire/ -- I-Mab  , a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced thepresentation of a poster highlighting Phase 1 optimized dose estimation data for givastomig monotherapy , a novel first-in-class Claudin18.2  and 4-1BB bispecific antibody, at SITC 2024. The conference is being held in Houston, Texas, from November 6-10, 2024.Title: Optimal dose estimation using an integrated approach from Phase I data ofgivastomig, a novel Claudin18.2×4-1BB bispecific antibody. Session: Poster Hall, George R. Brown Convention Center. A full copy of the poster will be available on the I-Mab website under the \"Innovation, Publications & Presentations\" tab on November 9, 2024.The program is being jointly developed through ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YY4cMKzXvpZlyMc6OlKWdw--~B/aD0xNjA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/eb81d0c969528762bc858c941b7a51e6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YY4cMKzXvpZlyMc6OlKWdw--~B/aD0xNjA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/eb81d0c969528762bc858c941b7a51e6"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/mab-present-givastomig-phase-1-110000694.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mab-present-givastomig-phase-1-110000694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4505","BK4080","IMAB","BK4526","BK4535","BK4139","BK4231","SITC"],"gpt_icon":1},{"id":"2478976105","title":"I-Mab to Participate at the Truist Securities BioPharma Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2478976105","media":"PR Newswire","labels":["Important Conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478976105?lang=en_us&edition=fundamental","pubTime":"2024-10-28 19:00","pubTimestamp":1730113200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ --I-Mab , a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on November 7, 2024.Sean Fu, PhD, MBA, Interim Chief Executive Officer  Joe Skelton, Chief Financial Officer  Phillip Dennis, MD, PhD, Chief Medical Officer  Tyler Ehler, Senior Director, Investor Relations. For more information, please contact your Truist Securities representative.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YY4cMKzXvpZlyMc6OlKWdw--~B/aD0xNjA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/eb81d0c969528762bc858c941b7a51e6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YY4cMKzXvpZlyMc6OlKWdw--~B/aD0xNjA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/eb81d0c969528762bc858c941b7a51e6"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/mab-participate-truist-securities-biopharma-110000380.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mab-participate-truist-securities-biopharma-110000380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Important Conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NQmain","CEO","IMAB","BK4535","QID","BK4139","BK4526","CFO","QLD","CMO","SQQQ","PSQ","MNQmain","TQQQ",".IXIC","BK4505"],"gpt_icon":1},{"id":"2478983442","title":"I-Mab Biopharma’s Strategic US Transition and Pipeline Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2478983442","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478983442?lang=en_us&edition=fundamental","pubTime":"2024-10-25 19:28","pubTimestamp":1729855728,"startTime":"0","endTime":"0","summary":"I-Mab Biopharma has completed the transition of its operations to the U.S., focusing on a streamlined organizational structure to enhance its immunotherapeutic pipeline. The company is advancing its clinical strategy with a disciplined capital approach, highlighting key developments in its drug candidates such as uliledlimab, givastomig, and ragistomig targeting various cancers. This strategic shift positions I-Mab to potentially capture significant market opportunities in the biotech sector.For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VaKCXGYM.Q2xBRfnsYVuuQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/4228d494699edc69b7f529ca87ad9ce2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VaKCXGYM.Q2xBRfnsYVuuQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/4228d494699edc69b7f529ca87ad9ce2"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/mab-biopharma-strategic-us-transition-112848683.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mab-biopharma-strategic-us-transition-112848683.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4526","BK4535","IMAB","BK4505"],"gpt_icon":0},{"id":"2474272466","title":"IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2474272466","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474272466?lang=en_us&edition=fundamental","pubTime":"2024-10-10 00:00","pubTimestamp":1728489613,"startTime":"0","endTime":"0","summary":"I-Mab Sponsored ADR  could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 . An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.As such, the Zacks rating upgrade for IMab is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.For the fisca","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/auhFPLcthJM50UYepXcODg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/auhFPLcthJM50UYepXcODg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imab-imab-moves-buy-rationale-160013006.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IMAB"],"gpt_icon":0},{"id":"2469819780","title":"I-MAB Appoints New Board Member and Audit Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2469819780","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469819780?lang=en_us&edition=fundamental","pubTime":"2024-09-23 19:27","pubTimestamp":1727090874,"startTime":"0","endTime":"0","summary":"I-MAB (IMAB) has released an update. I-MAB has announced a recent change in its Board of Directors, with Mr. Shuai Chen resigning for personal reas...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/i-mab-appoints-new-board-member-and-audit-committee?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/i-mab-appoints-new-board-member-and-audit-committee?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4526","MAB","BK4535","BK4505","BK4139","IMAB"],"gpt_icon":0},{"id":"2468258363","title":"Analysts Are Bullish on These Healthcare Stocks: Clene (CLNN), I-MAB (IMAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2468258363","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468258363?lang=en_us&edition=fundamental","pubTime":"2024-09-18 20:20","pubTimestamp":1726662045,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Clene (CLNN – Research Report) and I-MAB (IMAB – Res...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-clene-clnn-i-mab-imab?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-clene-clnn-i-mab-imab?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4505","CLNN","BK4526","HCSG","MAB","BK4139","BK4535","IMAB"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.i-mabbiopharma.com","stockEarnings":[{"period":"1week","weight":-0.0964},{"period":"1month","weight":-0.2935},{"period":"3month","weight":-0.2266},{"period":"6month","weight":-0.463},{"period":"1year","weight":-0.3735},{"period":"ytd","weight":-0.5054}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.014534},{"month":2,"riseRate":0.4,"avgChangeRate":-0.04256},{"month":3,"riseRate":0.4,"avgChangeRate":-0.12353},{"month":4,"riseRate":0.4,"avgChangeRate":0.05187},{"month":5,"riseRate":0.6,"avgChangeRate":0.06995},{"month":6,"riseRate":0.8,"avgChangeRate":0.101096},{"month":7,"riseRate":0.2,"avgChangeRate":-0.05589},{"month":8,"riseRate":0.2,"avgChangeRate":-0.159935},{"month":9,"riseRate":0.6,"avgChangeRate":-0.067835},{"month":10,"riseRate":0.2,"avgChangeRate":-0.080157},{"month":11,"riseRate":0.2,"avgChangeRate":-0.020879},{"month":12,"riseRate":0.75,"avgChangeRate":0.084038}],"exchange":"NASDAQ","name":"I-MAB","nameEN":"I-MAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"I-MAB(IMAB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest I-MAB(IMAB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"I-MAB,IMAB,I-MAB股票,I-MAB股票老虎,I-MAB股票老虎国际,I-MAB行情,I-MAB股票行情,I-MAB股价,I-MAB股市,I-MAB股票价格,I-MAB股票交易,I-MAB股票购买,I-MAB股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"I-MAB(IMAB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest I-MAB(IMAB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction